President Donald Trump’s work to lower prescription drug costs for patients will undoubtedly be one of his most significant legacies. From the legislation he recently signed to increase transparency among pharmacy benefit managers to the historic pricing deals he has negotiated with drug manufacturers, Trump has made more progress on this issue than any of his modern predecessors.
Yet while Trump’s energetic approach to drug pricing reform is admirable, prudence remains important, particularly when it comes to the “Most Favored Nation” pricing proposals that some conservatives in Congress are misguidedly championing.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.